HENDERSON, Nev.--(BUSINESS WIRE)--Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the third quarter ended September 30, 2022.
Management Commentary
“All of us at Ontrak Health are encouraged by the growing momentum in our sales pipeline, enhancements to our clinical model, and effectiveness of our AI-enhanced technology platform. It’s why I believe we are close to new customer contracts that will position us for a return to growth in 2023,” commented Founder, Executive Chairman, and Chief Executive Officer Terren Peizer.
Third Quarter 2022 Financial Results Highlights
- Revenue for the third quarter of 2022 was $2.8 million, representing an 85% decrease compared to the same period in 2021.
- Operating loss for the third quarter of 2022 was $(11.1) million compared to an operating loss of $(5.5) million for the same period in 2021.
- Adjusted EBITDA for the third quarter of 2022 was $(7.7) million compared to adjusted EBITDA of $(1.7) million for the same period in 2021.
- Net loss for the third quarter of 2022 was $(12.8) million, or an $(0.62) diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to net loss of $(7.9) million, or a $(0.54) diluted net loss per common share (after deduction for declared and undeclared preferred stock dividends) for the same period in 2021.
- Non-GAAP net loss for the third quarter of 2022 was $(9.4) million, or a $(0.48) non-GAAP diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to non-GAAP net loss of $(4.5) million, or a $(0.35) non-GAAP diluted net loss per common share (after deduction for declared and undeclared preferred stock dividends) for the same period in 2021.
Third Quarter 2022 and Recent Operating Highlights
- Total enrolled members numbered 1,365 at the end of Q3 2022.
- On August 26, 2022, the Company's board of directors ("Board") appointed James Messina to serve on the Board and on its Audit Committee, Nominations and Governance Committee, and Compensation Committee. This appointment follows the resignation of Robert Rebak from the Board and each committee of the Board on which Mr. Rebak served.
- On August 18, 2022, the Company's management approved a restructuring plan as part of management's cost saving measures in order to reduce its operating costs, optimize its business model and help align with its previously stated strategic initiatives, reducing approximately 34% of positions and $7.7 million of annual compensation related costs, as well as approximately $3.0 million of annual third-party costs. During Q3 2022, the Company incurred a total of approximately $0.9 million of termination benefits to the impacted employees, including severance payments and benefits.
- On August 2, 2022, the Company entered into a securities purchase agreement with institutional investors for the purchase and sale of five million shares of the Company’s common stock at an at-the-market purchase price of $0.80 per share in a registered direct offering. The offering closed on August 4, 2022 and the Company received total net proceeds of approximately $3.3 million (excluding $0.7 million of total offering related fees).
- On July 25, 2022, the Company appointed Dr. Judy Feld as Chief Medical Officer ("CMO"), following Dr. Robert Accordino’s resignation effective July 29, 2022 from his role as CMO.
- On July 15, 2022, the Company repaid $7.5 million of the remaining GS loan balance, with $2.6 million of its cash on hand and $5.0 million draw down on the Keep Well Agreement, which represented full payoff of the GS loan agreement.
- The Company is finalizing an amendment to the Master Note Purchase Agreement, pursuant to which it expects the maturity date will be extended to 2024.
Financial Outlook
The following outlook is based on information available as of the date of this press release and is subject to change in the future. This outlook solely represents existing and planned enrollment launches, and program expansions with current health plan partners.
For the year ending December 31, 2022, the Company confirms its existing revenue outlook:
- 2022 revenue in the range of $14 - $16 million.
Conference Call & Webcast Details
The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Ontrak, Inc.
Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Learn more at www.ontrakhealth.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements may include for example statements regarding: the strength of our pipeline and our ability to convert pipeline opportunities to contracts in the fourth quarter of 2022 and beyond; our ability to deliver durable value-based outcomes for medically complex populations; the benefits of expanding our augmented intelligence capabilities throughout the member care journey; our ability to return to a growth trajectory; our ability to achieve our intended path to profitability; our ability to effectively align our resources, manage our operating costs and address the change in staffing needs; our ability to draw on the remaining available amount, as well as extend the maturity date on the note purchase agreement with Acuitas Capital LLC; and driving accelerated growth, expansion and performance. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, dependence on key personnel and the ability to recruit, retain and develop a large and diverse workforce; high customer concentration and the ability of our customers to terminate our contracts for convenience; intense competition and substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; limited operating history; our inability to execute our business plan; increase our revenue and achieve profitability; lower than anticipated eligible members under our contracts; our inability to recognize revenue; the adequacy of our existing cash resources and anticipated capital commitments to enable us to continue as a going concern; our ability to raise additional capital when needed; lack of outcomes and statistically significant formal research studies; difficulty enrolling new members and maintaining existing members in our programs; the risk that the treatment programs might not be effective; difficulty in developing, exploiting and protecting proprietary technologies; continued business disruption and related risks resulting from the outbreak of the novel coronavirus 2019; general economic conditions, nationally and globally, and their effect on the market for our services, competitive pressures and trends in our industry and our ability to successfully compete with our competitors, changes in laws, regulations, or policies, our receipt of a deficiency notification from the Nasdaq Stock Market regarding the trading price of our common stock, and risks related to our ability to realize the potential benefits of and to effectively integrate acquisitions. You are urged to consider statements that include the words “may,” “will,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made and based on information available to us on the date hereof, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
EBITDA consists of net loss before interest, taxes, depreciation, and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, restructuring, severance and related costs, acquisition related costs, and loss (gain) on change in fair value of warrant liability and contingent liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
Non-GAAP net loss consists of net loss adjusted for stock-based compensation, write-off of debt discount costs, restructuring, severance and related costs, acquisition related costs and loss (gain) on change in fair value of warrant liabilities and contingent liability. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms EBITDA, Adjusted EBITDA, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. None of either EBITDA, Adjusted EBITDA, Non-GAAP net loss or Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.
ONTRAK, INC. Consolidated Statements of Operations (in thousands, except per share data) (unaudited) |
|||||||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Revenue |
$ |
2,843 |
|
|
$ |
18,594 |
|
|
$ |
12,004 |
|
|
$ |
73,801 |
|
Cost of revenue |
|
1,436 |
|
|
|
5,856 |
|
|
|
6,488 |
|
|
|
27,125 |
|
Gross profit |
|
1,407 |
|
|
|
12,738 |
|
|
|
5,516 |
|
|
|
46,676 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
2,833 |
|
|
|
4,563 |
|
|
|
9,113 |
|
|
|
13,531 |
|
Sales and marketing |
|
1,151 |
|
|
|
2,269 |
|
|
|
3,893 |
|
|
|
7,839 |
|
General and administrative |
|
7,552 |
|
|
|
11,325 |
|
|
|
27,694 |
|
|
|
33,966 |
|
Restructuring, severance and related costs |
|
934 |
|
|
|
49 |
|
|
|
934 |
|
|
|
1,339 |
|
Total operating expenses |
|
12,470 |
|
|
|
18,206 |
|
|
|
41,634 |
|
|
|
56,675 |
|
Operating loss |
|
(11,063 |
) |
|
|
(5,468 |
) |
|
|
(36,118 |
) |
|
|
(9,999 |
) |
|
|
|
|
|
|
|
|
||||||||
Other expense, net |
|
(1,241 |
) |
|
|
(361 |
) |
|
|
(3,213 |
) |
|
|
(1,004 |
) |
Interest expense, net |
|
(440 |
) |
|
|
(2,054 |
) |
|
|
(2,996 |
) |
|
|
(6,090 |
) |
Loss before income taxes |
|
(12,744 |
) |
|
|
(7,883 |
) |
|
|
(42,327 |
) |
|
|
(17,093 |
) |
Income tax expense |
|
(20 |
) |
|
|
— |
|
|
|
(140 |
) |
|
|
— |
|
Net loss |
$ |
(12,764 |
) |
|
$ |
(7,883 |
) |
|
$ |
(42,467 |
) |
|
$ |
(17,093 |
) |
Dividends on preferred stock - declared and undeclared |
|
(2,239 |
) |
|
|
(2,239 |
) |
|
|
(6,716 |
) |
|
|
(6,716 |
) |
Net loss attributable to common stockholders |
$ |
(15,003 |
) |
|
$ |
(10,122 |
) |
|
$ |
(49,183 |
) |
|
$ |
(23,809 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss per common share, basic and diluted |
$ |
(0.62 |
) |
|
$ |
(0.54 |
) |
|
$ |
(2.24 |
) |
|
$ |
(1.31 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted-average common shares outstanding, basic and diluted |
|
24,339 |
|
|
|
18,915 |
|
|
|
21,995 |
|
|
|
18,236 |
|
ONTRAK, INC. Consolidated Balance Sheets (in thousands, except share and per share data) |
|||||||
|
September 30, |
|
December 31, |
||||
|
2022 |
|
2021 |
||||
Assets |
(unaudited) |
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
7,253 |
|
|
$ |
58,824 |
|
Restricted cash - current |
|
4,477 |
|
|
|
6,716 |
|
Receivables, net |
|
4,590 |
|
|
|
5,938 |
|
Unbilled receivables |
|
412 |
|
|
|
3,235 |
|
Deferred costs - current |
|
145 |
|
|
|
600 |
|
Prepaid expenses and other current assets |
|
2,179 |
|
|
|
5,019 |
|
Total current assets |
|
19,056 |
|
|
|
80,332 |
|
Long-term assets: |
|
|
|
||||
Property and equipment, net |
|
2,505 |
|
|
|
3,785 |
|
Restricted cash - long-term |
|
204 |
|
|
|
406 |
|
Goodwill |
|
5,713 |
|
|
|
5,713 |
|
Intangible assets, net |
|
1,430 |
|
|
|
2,346 |
|
Other assets |
|
1,038 |
|
|
|
444 |
|
Operating lease right-of-use assets |
|
712 |
|
|
|
656 |
|
Total assets |
$ |
30,658 |
|
|
$ |
93,682 |
|
|
|
|
|
||||
Liabilities and stockholders' equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
1,768 |
|
|
$ |
1,001 |
|
Accrued compensation and benefits |
|
2,095 |
|
|
|
2,343 |
|
Deferred revenue |
|
288 |
|
|
|
441 |
|
Current portion of operating lease liabilities |
|
655 |
|
|
|
595 |
|
Other accrued liabilities |
|
2,710 |
|
|
|
5,953 |
|
Total current liabilities |
|
7,516 |
|
|
|
10,333 |
|
Long-term liabilities: |
|
|
|
||||
Long-term debt, net |
|
9,218 |
|
|
|
35,792 |
|
Long-term operating lease liabilities |
|
711 |
|
|
|
932 |
|
Long-term finance lease liabilities |
|
8 |
|
|
|
136 |
|
Other liabilities |
|
— |
|
|
|
934 |
|
Total liabilities |
|
17,453 |
|
|
|
48,127 |
|
Commitments and contingencies |
|
|
|
||||
|
|
|
|
||||
Stockholders' equity: |
|
|
|
||||
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of September 30, 2022 and December 31, 2021 |
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value, 500,000,000 shares authorized; 26,914,155 and 20,680,186 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively |
|
3 |
|
|
|
2 |
|
Additional paid-in capital |
|
446,837 |
|
|
|
436,721 |
|
Accumulated deficit |
|
(433,635 |
) |
|
|
(391,168 |
) |
Total stockholders' equity |
|
13,205 |
|
|
|
45,555 |
|
Total liabilities and stockholders' equity |
$ |
30,658 |
|
|
$ |
93,682 |
|
ONTRAK, INC. Consolidated Statements of Cash Flows (in thousands, unaudited) |
|||||||
|
For the Nine Months Ended September 30, |
||||||
|
2022 |
|
2021 |
||||
Cash flows from operating activities |
|
|
|
||||
Net loss |
$ |
(42,467 |
) |
|
$ |
(17,093 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Stock-based compensation expense |
|
6,282 |
|
|
|
8,871 |
|
Write-off of debt issuance costs |
|
3,334 |
|
|
|
— |
|
Depreciation expense |
|
2,222 |
|
|
|
658 |
|
Amortization expense |
|
1,946 |
|
|
|
2,181 |
|
Gain on forgiveness of PPP loan |
|
— |
|
|
|
(171 |
) |
Change in fair value of warrants |
|
(121 |
) |
|
|
— |
|
Change in fair value of contingent consideration |
|
— |
|
|
|
1,305 |
|
401(k) employer match in common shares |
|
528 |
|
|
|
860 |
|
Common stock issued for consulting services |
|
102 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
|
1,348 |
|
|
|
11,478 |
|
Unbilled receivables |
|
2,823 |
|
|
|
(834 |
) |
Prepaid expenses and other current assets |
|
2,966 |
|
|
|
1,674 |
|
Accounts payable |
|
758 |
|
|
|
(285 |
) |
Deferred revenue |
|
(153 |
) |
|
|
(15,633 |
) |
Leases liabilities |
|
(160 |
) |
|
|
(208 |
) |
Other accrued liabilities |
|
(1,928 |
) |
|
|
(3,914 |
) |
Net cash used in operating activities |
|
(22,520 |
) |
|
|
(11,111 |
) |
Cash flows from investing activities |
|
|
|
||||
Purchase of property and equipment |
|
(1,004 |
) |
|
|
(3,865 |
) |
Net cash used in investing activities |
|
(1,004 |
) |
|
|
(3,865 |
) |
Cash flows from financing activities |
|
|
|
||||
Repayments of 2024 Notes |
|
(39,194 |
) |
|
|
— |
|
Proceeds from Keep Well Notes |
|
11,000 |
|
|
|
— |
|
Proceeds from issuance of common stock |
|
4,000 |
|
|
|
— |
|
Common stock issuance costs |
|
(706 |
) |
|
|
— |
|
Dividends paid |
|
(2,239 |
) |
|
|
(6,712 |
) |
Debt issuance costs |
|
(792 |
) |
|
|
— |
|
Proceeds from warrant exercise |
|
— |
|
|
|
58 |
|
Proceeds from options exercise |
|
— |
|
|
|
5,584 |
|
Finance lease obligations |
|
(226 |
) |
|
|
(243 |
) |
Financed insurance premium payments |
|
(2,325 |
) |
|
|
(2,154 |
) |
Payment of taxes related to net-settled stock awards |
|
(6 |
) |
|
|
— |
|
Net cash used in financing activities |
|
(30,488 |
) |
|
|
(3,467 |
) |
Net change in cash and restricted cash |
|
(54,012 |
) |
|
|
(18,443 |
) |
Cash and restricted cash at beginning of period |
|
65,946 |
|
|
|
103,210 |
|
Cash and restricted cash at end of period |
$ |
11,934 |
|
|
$ |
84,767 |
|
|
|
|
|
||||
Supplemental disclosure of cash flow information: |
|
|
|
||||
Interest paid |
$ |
2,307 |
|
|
$ |
5,483 |
|
Income taxes paid |
|
210 |
|
|
|
91 |
|
Non-cash financing and investing activities: |
|
|
|
||||
Common stock issued in connection with Keep Well Agreement |
$ |
1,249 |
|
|
$ |
— |
|
Warrants issued in connection with 2024 Notes |
|
458 |
|
|
|
— |
|
Financed insurance premium |
|
352 |
|
|
|
— |
|
Warrants issued in connection with Keep Well Notes |
|
322 |
|
|
|
— |
|
Common stock issued to settle contingent consideration |
|
293 |
|
|
|
— |
|
Accrued debt issuance costs |
|
138 |
|
|
|
— |
|
Finance lease and accrued purchases of property and equipment |
|
31 |
|
|
|
230 |
|
ONTRAK, INC. Reconciliation of Non-GAAP Measures (in thousands, except per share data) |
||||||||||||||||
Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA |
||||||||||||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Operating loss |
|
$ |
(11,063 |
) |
|
$ |
(5,468 |
) |
|
$ |
(36,118 |
) |
|
$ |
(9,999 |
) |
Depreciation expense |
|
|
798 |
|
|
|
276 |
|
|
|
2,222 |
|
|
|
658 |
|
Amortization expense (1) |
|
|
412 |
|
|
|
525 |
|
|
|
1,217 |
|
|
|
1,547 |
|
EBITDA |
|
|
(9,853 |
) |
|
|
(4,667 |
) |
|
|
(32,679 |
) |
|
|
(7,794 |
) |
Stock-based compensation expense |
|
|
1,219 |
|
|
|
2,910 |
|
|
|
6,282 |
|
|
|
8,871 |
|
Restructuring, severance and related costs (2) |
|
|
934 |
|
|
|
49 |
|
|
|
934 |
|
|
|
1,339 |
|
Acquisition related costs (3) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
583 |
|
Adjusted EBITDA |
|
$ |
(7,700 |
) |
|
$ |
(1,708 |
) |
|
$ |
(25,463 |
) |
|
$ |
2,999 |
|
Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share |
||||||||||||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Net loss |
|
$ |
(12,764 |
) |
|
$ |
(7,883 |
) |
|
$ |
(42,467 |
) |
|
$ |
(17,093 |
) |
Stock-based compensation expense |
|
|
1,219 |
|
|
|
2,910 |
|
|
|
6,282 |
|
|
|
8,871 |
|
Write-off of debt issuance costs (4) |
|
|
1,311 |
|
|
|
— |
|
|
|
3,334 |
|
|
|
— |
|
Restructuring, severance and related costs (2) |
|
|
934 |
|
|
|
49 |
|
|
|
934 |
|
|
|
1,339 |
|
Gain on change in fair value of warrant liabilities |
|
|
(70 |
) |
|
|
— |
|
|
|
(121 |
) |
|
|
(29 |
) |
Loss on change in fair value of contingent liability (5) |
|
|
— |
|
|
|
470 |
|
|
|
— |
|
|
|
1,305 |
|
Acquisition related costs (3) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
583 |
|
Gain on forgiveness of PPP loan (6) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(171 |
) |
Non-GAAP net loss |
|
|
(9,370 |
) |
|
|
(4,454 |
) |
|
|
(32,038 |
) |
|
|
(5,195 |
) |
Dividends on preferred stock - declared and undeclared |
|
|
(2,239 |
) |
|
|
(2,239 |
) |
|
|
(6,716 |
) |
|
|
(6,716 |
) |
Non-GAAP net loss attributable to common stockholders |
|
$ |
(11,609 |
) |
|
$ |
(6,693 |
) |
|
$ |
(38,754 |
) |
|
$ |
(11,911 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per common share - basic and diluted |
|
$ |
(0.62 |
) |
|
$ |
(0.54 |
) |
|
$ |
(2.24 |
) |
|
$ |
(1.31 |
) |
Non-GAAP net loss per common share - basic and diluted |
|
|
(0.48 |
) |
|
|
(0.35 |
) |
|
|
(1.76 |
) |
|
|
(0.65 |
) |
Weighted-average common shares outstanding - basic and diluted |
|
|
24,339 |
|
|
|
18,915 |
|
|
|
21,995 |
|
|
|
18,236 |
|
_______________________ |
||
(1) |
Relates to operating and financing ROU assets and acquired intangible assets. |
|
(2) |
Includes one-time severance and related benefit costs related to reduction in workforce. |
|
(3) |
Includes external legal, accounting, and advisory costs associated with acquisition activity. |
|
(4) |
Relates to write-off of debt issuance costs on our 2024 Notes. |
|
(5) |
Relates to loss resulting from change in fair value of contingent liability related to a stock price guarantee associated with an acquisition. |
|
(6) |
Relates to gain recognized upon forgiveness of LifeDojo's PPP loan in May 2021. |
|
